LON:MTPH Biodexa Pharmaceuticals (MTPH) Share Price, News & Analysis GBX 18 +17.05 (+1,794.74%) (As of 03/27/2023) Add Compare Share Share Stock Analysis Stock Analysis Get Biodexa Pharmaceuticals alerts: Email Address About Biodexa Pharmaceuticals Stock (LON:MTPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MTPH alerts:Sign Up Key Stats Today's Range 12.50▼ 2050-Day Range 18▼ 1852-Week Range 0.90▼ 20Volume73,672 shsAverage Volume617,252 shsMarket Capitalization£31.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMidatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Read More… Why Are Buffett, Bezos, and Musk Fleeing Tech? Here's What To Do Now... (Ad)The financial world is on high alert. Billionaires like Warren Buffett, Jeff Bezos, and Elon Musk are dumping their tech stocks at a pace we've never seen before. What do they know that's pushing them out? One that Fortune is calling:"The Great Cash Out".Click here to get the details now. Receive MTPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biodexa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MTPH Stock News HeadlinesWhat's Going On With Biodexa Pharmaceuticals Stock?May 21, 2024 | msn.comBiodexa shares rally 126% on rapamycin licensing dealApril 26, 2024 | seekingalpha.comIntroducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.September 17, 2024 | Brownstone Research (Ad)SLRX Salarius Pharmaceuticals, Inc.March 28, 2024 | seekingalpha.comBiodexa stock slides 7% amid data for two drug studiesFebruary 23, 2024 | msn.comBiodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma PatientsFebruary 8, 2024 | markets.businessinsider.comBiodexa stock jumps on allowance of U.S. patent covering TolimidoneFebruary 7, 2024 | msn.comBiodexa Announces Allowance of U.S. Patent Covering TolimidoneFebruary 7, 2024 | tmcnet.comSee More Headlines MTPH Stock Analysis - Frequently Asked Questions How have MTPH shares performed this year? Biodexa Pharmaceuticals' stock was trading at GBX 18 at the beginning of the year. Since then, MTPH stock has increased by 0.0% and is now trading at GBX 18. View the best growth stocks for 2024 here. How were Biodexa Pharmaceuticals' earnings last quarter? Biodexa Pharmaceuticals Plc (LON:MTPH) released its quarterly earnings results on Thursday, September, 10th. The company reported ($64.00) earnings per share (EPS) for the quarter. How do I buy shares of Biodexa Pharmaceuticals? Shares of MTPH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Biodexa Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biodexa Pharmaceuticals investors own include Aldeyra Therapeutics (ALDX), Barclays (BARC), Telefonaktiebolaget LM Ericsson (publ) (ERIC), Futura Medical (FUM), Lloyds Banking Group (LLOY), Biodexa Pharmaceuticals (MTP) and Intec Pharma (NTEC). Company Calendar Last Earnings9/10/2020Today9/17/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryComputer Software Current SymbolLON:MTPH CUSIPN/A CIKN/A Webwww.midatechpharma.com Phone+44-1235-841575FaxN/AEmployees18Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-5,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-95.47% Return on Assets-52.50% Debt Debt-to-Equity Ratio9.52 Current Ratio5.28 Quick Ratio5.28 Sales & Book Value Annual Sales£645,000.00 Price / Sales48.38 Cash FlowGBX 20.53 per share Price / Cash Flow0.88 Book ValueGBX 152 per share Price / Book0.12Miscellaneous Outstanding Shares173,350,000Free FloatN/AMarket Cap£31.20 million OptionableNot Optionable Beta1.22 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (LON:MTPH) was last updated on 9/17/2024 by MarketBeat.com Staff From Our PartnersSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredWall Street Insider Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredKamala Harris and The Woke Progressive NightmareNew research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election M...Paradigm Press | SponsoredJeff Bezos Just Humiliated Elon MuskThe Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next...InvestorPlace | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.